{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT03697161",
      "orgStudyIdInfo": {
        "id": "OV101-17-001"
      },
      "organization": {
        "fullName": "Healx AI",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study of OV101 in Individuals With Fragile X Syndrome",
      "officialTitle": "A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome",
      "acronym": "ROCKET"
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to assess the safety, tolerability and efficacy of oral OV101 (gaboxadol) in subjects with Fragile X syndrome."
    },
    "conditionsModule": {
      "conditions": [
        "Fragile X Syndrome (FXS)"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 36,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "OV101 (gaboxadol) Regimen 1",
          "type": "EXPERIMENTAL",
          "description": "Once Daily",
          "interventionNames": [
            "Drug: OV101 (gaboxadol)"
          ]
        },
        {
          "label": "OV101 (gaboxadol) Regimen 2",
          "type": "EXPERIMENTAL",
          "description": "Twice Daily",
          "interventionNames": [
            "Drug: OV101 (gaboxadol)"
          ]
        },
        {
          "label": "OV101 (gaboxadol) Regimen 3",
          "type": "EXPERIMENTAL",
          "description": "Three Times Daily",
          "interventionNames": [
            "Drug: OV101 (gaboxadol)"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "OV101 (gaboxadol)",
          "description": "OV101 (gaboxadol)",
          "armGroupLabels": [
            "OV101 (gaboxadol) Regimen 1",
            "OV101 (gaboxadol) Regimen 2",
            "OV101 (gaboxadol) Regimen 3"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of Participants With Treatment Emergent Adverse Events (TEAE)",
          "description": "Number of Participants with Treatment Emergent Adverse Events",
          "timeFrame": "Week 12"
        }
      ],
      "otherOutcomes": [
        {
          "measure": "Clinical Global Impressions- Improvement (CGI-I)",
          "timeFrame": "Week 12"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Is male and 13 to 22 years old (inclusive) at the time of informed consent.\n* Has a diagnosis of FXS with a confirmed FMR1 full mutation (â‰¥200 CGG repeats).\n\nExclusion Criteria:\n\n* Concomitant disease or condition that are clinically significant and would limit study participation\n* Clinically significant lab abnormalities or vital signs at the time of screening\n* History of uncontrollable seizure disorder or seizure episodes within 6 months of screening or change in the anticonvulsant pharmacotherapy in the past 3 months.\n* Unable or does not have a caregiver able to comply with study requirements.\n* Enrolled in any clinical trial within the 30 days before screening.",
      "healthyVolunteers": false,
      "sex": "MALE",
      "genderBased": true,
      "minimumAge": "13 Years",
      "maximumAge": "22 Years",
      "stdAges": [
        "CHILD",
        "ADULT"
      ]
    }
  }
}